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INTRODUCTION
The synapse
In the late 19th century there were a lot of agonizing argues between the scientists. One of 
the most famous, at least within neuroscience, is the argue between the reticularists and the 
neuronists, personiﬁed by the leading neuroscientists and histologists of the time Camillo 
Golgi and Santiago Ramón y Cajal (Rapport, 2005). The reticularists, with the Italian Golgi 
in front, believed that the nervous tissue in the brain was made up of one continuous net of 
branches – a syncytial system. Cajal and the neuronists meant that the neurons in the brain 
were separated with small gaps (the neuron doctrine). We now understand that they actually 
argued about the existence of the synapse.
In 1906 Golgi and Cajal shared the Nobel Prize in medicine for their studies of the structure 
of the nervous system. At the time the neuron doctrin was generally recognized to be the most 
probable, and even Golgi admitted that in his Nobel lecture (Golgi, 1907).
In 1887, the same year as Cajal started his histological studies, the Norwegian explorer 
Fridtjof Nansen gave out his doctor thesis about the nervous system of the hagﬁsh. 
Nansen wrote: “I have not yet observed a single case of indubitable anastomosis between 
protoplasmatic processes. I believe, thus, that I am entitled to afﬁrm that a direct combination 
between ganglion cells, by direct anastomosis of the protoplasmic processes, does not exist.” 
(Nansen, 1887). Nansen ended his neuroscientiﬁc career after he was conferred the doctor’s 
degree. If he had continued, maybe he would have received the Nobel Prize in medicine in 
1906. Instead he got another Nobel Prize, namely the Peace Prize in 1922.
 
Cajal and Nansen were correct about the existence of a gap between the nerve cells. However, 
they had never seen these gaps, only some small dots in the light microscope representing the 
nerve terminals. The actual gap was not possible to visualize before the electron microscope 
was invented.
The gap is a part of the synapse, and this is where the nerve cells communicate with each 
other (ﬁg 1). Each neuron forms about 1000 synapses with neighboring cells, meaning that the 
brain consists of about 1015 synapses. Understanding synaptic transmission is fundamental in 
the understanding of the functions of the brain. 
Fig 1: The synapse. The presynaptic terminal (yellow) contacts the postsynaptic dendrite (red). Both 
are enclosed by glial membranes (green). The cartoon on the left is fused together with the electron 
micrograph on the right. The black dots on the micrograph are gold particles labeling glutamate. 
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The chemical synapse consists of a presynaptic and a postsynaptic membrane and a 
synaptic cleft in between. For a signal to be transmitted from one nerve cell to another, 
neurotransmitters have to be released from the presynaptic part of the synapse. The 
neurotransmitters will diffuse across the synaptic cleft and bind to a postsynaptic receptor. 
This receptor activation is responsible for the effects in the postsynaptic cell, e.g. a 
depolarization of the cell leading to an action potential.
The presynaptic nerve terminal contains a cluster of vesicles. These vesicles hold the 
transmitters. The synaptic vesicles located in the “readily releasable pool” just opposite the 
synaptic membrane, the active zone, will in the presence of increased intracellular Ca2+-
concentrations move towards and fuse with the synaptic membrane. The lumen of the vesicles 
will then be a part of the extracellular space, the synaptic cleft, and the transmitters will 
diffuse freely. This process is called regulated exocytosis.
The postsynaptic receptors are located on the other side of the synaptic cleft. Each of the 
different transmitters has a speciﬁc set of receptors. The receptors are membrane-spanning 
proteins with speciﬁc binding sites for transmitters.
Action potentials in nerve terminals lead to release of transmitters
In most nerve cells the resting membrane potential is about -65 mV. This means that the inside 
of the cells are slightly negative in relation to the outside. The resting potential is caused 
by the difference in ion concentration between the inside and outside of the cells (the K+-
concentration is high inside the cells and low outside, while Na+ has an opposite distribution), 
and the leakage of ions through selective ion channels, through which leakage of  K+ is the 
most important. When K+ is leaking out of the cell, a negative electric force will arise inside 
the cell.
The cell membrane in the nerve cell contains voltage gated Na+-channels. They will open 
when the membrane depolarizes – meaning that Na+ will ﬂow into the neuron along the 
inward electrochemical gradient (higher Na+ concentration on the outside and a negative 
membrane potential). The following inﬂux of Na+ overwhelms the dominant potassium 
efﬂux of the resting membrane. The inﬂux of sodium leads to a positive feedback cycle – the 
opening of Na+-channels leads to Na+ inﬂux, depolarizing more of the cell membrane, opening 
more of the Na+-channels. In this way the depolarization will run along the nerve cell. 
When the cell membrane is depolarized to +55 mV, the sodium inﬂux will end because the 
inward force from the concentration difference and the outward electric force equalize each 
other. The Na+-channels close, voltage gated K+-channels open and the membrane repolarizes. 
Voltage gated Ca2+-channels are located close to the active zone of the nerve terminals. They 
open when the membrane is depolarized. The depolarization is normally caused by action 
potentials, but can be caused by pathological conditions, e.g. shortage of energy (the cell will 
not be able to maintain the difference in ion concentration across the membrane) or severe 
electrolyte disturbance. One can trigger the calcium inﬂux in the terminals experimentally 
by depolarizing the cells, either by an electrode (Galvani did it with a charged scalpel) or 
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chemically by e.g. increasing the extracellular potassium concentration. 
Calcium inﬂux through the open Ca2+-channels is driven by a very large inward 
electrochemical force. The inﬂux will cause a marked rise in the local calcium concentration 
(more than thousand folds) in the active zone within a few hundred microseconds. The 
calcium entry triggers an interplay with a variety of proteins (e.g. the SNARE proteins) 
leading to vesicular release of transmitters. 
Neurotransmitters
A neurotransmitter is a substance which has an effect on postsynaptic cells when it is released 
from the nerve terminals. The transmitters could be excitatory, meaning that they depolarize 
the target cell and possibly lead to a new action potential or inhibitory, in which case they 
hyperpolarize the target cell, making it harder to trigger action potentials. Glutamate and γ-
aminobutyric acid (GABA) are the most common excitatory and inhibitory transmitters in the 
brain (Ottersen and Storm-Mathisen, 1984). 
Excitatory transmitters – glutamate
Glutamate was ﬁrst suspected to have an important transmitter role in the late 1950. 
Electrophysiological studies showed excitatory actions in neurons when glutamate was added 
(Curtis et al. 1960). Glutamate was not generally accepted as an excitatory transmitter before 
the 1980s. Contributing to establishing glutamate as a transmitter was that glutamatergic 
pathways were characterized with immunocytochemistry, and it was demonstrated that 
glutamate was released from nerve terminals by way of Ca2+ dependent exocytosis (Storm-
Mathisen et al., 1983; Fonnum 1984; Stom-Mathisen et al., 1986; Ottersen et al., 1990). 
Glutamate receptors
There are two categories of glutamate receptors. The ionotropic receptors, which directly 
open ion channels and the metabotropic receptors, which have indirect effects through second 
messengers. Glutamate always give excitatory postsynaptic responses through activation of 
the ionotropic receptors, while activation of metabotropic receptors have a modulatory effect 
on synaptic transmission; it can either increase or decrease synaptic activity, depending on the 
type of metabotropic receptor that is activated. 
The major types of ionotropic glutamate receptors are named after the synthetic substances 
that activate them; alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA), 
kainate and N-methyl-D-aspartate (NMDA). The non-NMDA receptors gates cation channels 
that are permeable to sodium and potassium, and is responsible for the large early part of 
the excitatory postsynaptic potential (EPSP) – the fast depolarization of the postsynaptic 
membrane (Hollmann and Heinemann, 1994).
The NMDA receptors differ from the non-NMDA receptors in their characteristics. They are 
highly permeable to calcium in addition to sodium and potassium. Calcium has effects beyond 
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depolarizing the membrane. It activates calcium dependent enzymes and second messenger 
systems that can have a variety of effects in the cell. 
Opening of a NMDA-activated channel usually requires that the membrane is depolarized 
before activation, because a voltage sensitive block caused by a magnesium ion must be 
removed. This means that NMDA receptors often are dependent on concomitant activation of 
other excitatory receptors to function. NMDA receptors also require a co-agonist, glycine or 
D-serine, in addition to glutamate for activation. NMDA receptor activation may lead to long-
term changes in the neuronal function, but if they are strongly activated also to toxic effects. 
Excitotoxicity
The excitatory synapse is a ﬁne-tuned system. High extracelllular concentrations of glutamate 
can lead to cell death, through “overactivation” of especially the NMDA receptors. This 
will lead to increased inﬂux of Ca2+, which will trigger “death cascades” in the neuron, e.g 
mitochondrial dysfunction, which can generate free radicals, and activation of proteases 
that initiate apoptosis – cell death. Glutamate in toxic amounts can be seen in conditions 
like ischemic stroke and severe epilepsy. Therefore, there has been a goal to develop drugs 
which can protect the neuron from glutamate, such as glutamate receptor antagonists. 
Unfortunately most of these attempts have failed because of the severe side effects caused by 
blocking glutamate receptors: sedation, impaired memory, psychomotor retardation, cognitive 
impairment and even schizophrenia-like symptoms like hallucinations and psychosis (Doble, 
1999). In other words, the glutamate effect should be neither too weak nor too strong.
The neurotoxic effect of glutamate is called excitotoxicity (Olney, 1969). It has been proved 
that the effect is due to activation of glutamate receptors, because adding speciﬁc antagonists 
for instance to a cell culture will prevent the cell death caused by glutamate (Choi et al., 
1987).
The recirculation of glutamate
Because glutamate can potentially damage nerve cells, it is essential to efﬁciently remove 
it from the synaptic cleft where it activates the receptors (Danbolt, 2001). In addition, it is 
economical for the nerve cell if the released glutamate is transported back to the neuron for 
transmitter purposes. Also cellular glutamate uptake is necessary for keeping a high signal to 
noise ratio in synaptic transmission. Glutamate is mostly taken up across cell membrane by 
specialized transporter proteins. They are highly effective as they maintain a concentration 
gradient across the cell membrane of several thousand folds. Five such high afﬁnity sodium 
dependent excitatory amino acid transporters (EAATs) have been cloned (Danbolt, 2001): 
EAAT1 (GLAST), EAAT2 (GLT), EAAT3 (EAAC), EAAT4 and EAAT5. EAAT1-3 are 
distributed almost throughout the whole brain, EAAT4 is conﬁned to the cerebellum and 
EAAT5 is located only in the retina. EAAT1 and 2 are primarily located on astrocytes, while 
EAAT3 and 4 are mainly situated in somatodendritic compartments of neurons. 
 
It is three possible pathways of removal of glutamate from the synaptic cleft. Firstly, it could 
be taken up by EAAT1 and EAAT2 in astrocytic processes surrounding the synapse. Secondly, 
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it could be taken up by glutamate transporters in the presynaptic membrane. Even though 
this glutamate transporter protein is not deﬁnitely identiﬁed, it has been shown that there is 
a transporter in the EAAT-family present in the presynaptic membrane as demonstrated by 
uptake of D-aspartate (a glutamate analogue) in the terminals (Gundersen et al., 1993; 1995) 
as well as by immunocytochemistry of EAAT2 (Chen et al., 2004; Suchak et al., 2003; Furnes 
et al., 2008). Thirdly, glutamate could be removed by glutamate transporters on postsynaptic 
dendrites, as observed for EAAT3 in several brain regions (Furuta et al., 1997; Shashidharan 
et al., 1997) and for EAAT4 in the cerebellum (Dehnes et al., 1998).  
When glutamate is taken up by transporters in the astrocytic membrane, it starts a journey that 
may lead back to an excitatory vesicle in a nerve terminal. Inside the astrocyte, glutamate is 
transformed to glutamine by the glial speciﬁc enzyme glutamine synthetase (Norenberg MD 
and Martinez-Hernandez A, 1979; Derouiche A and Frotscher M., 1991)
Glutamine is then released from the astrocyte into the extracellular space through a system 
N glutamine transporter (SN) (Chaudhry et al.,, 2002). Glutamine has no effect on any 
receptors, and may be released with no risk of excitotoxicity. The released glutamine is then 
taken up into nerve terminals by a system A neuronal glutamine transporter (SAT) (Chaudhry 
et al., 2002). Inside the terminal it is converted back to glutamate by phosphate-activated 
glutaminase (PAG) which is located in the mitochondrial outer membrane (Kvamme et 
al., 2008). Finally glutamate enters excitatory vesicles through the vesicular glutamate 
transporters (VGLUTs) (Fremeau et al., 2004). The glutamate is now recycled and again ready 
to be released into the synaptic cleft (for evidence for the glutamate glutamine cycle, see e.g. 
Pow and Crook, 1996).
Background of the project
Aspartate
At the time I started my PhD studies there were dissensions concerning whether aspartate was 
a neurotransmitter. Aspartate was known to have excitatory properties and there were several 
ﬁndings that indicated a transmitter role for aspartate (see Gundersen and Storm-Mathisen, 
2000 for a thorough review).
Aspartate should fulﬁll the following four criteria to be called a neurotransmitter: Aspartate 
should  (1) be synthesized in the neuron, (2) be present in the nerve terminal and released 
from synaptic vesicles by regulated exocytosis, (3) have a receptor effect which can be 
imitated by adding exogenous substance into the system, and (4) be removed from the 
extracellular space by speciﬁc mechanisms (Schwartz, 2000). 
(1) Aspartate was known to be synthesized in the neuron from glutamate through oxaloacetate 
by aspartate aminotransferase (Kugler P, 1987; Martinez-Rodriguez and Arenas, 1988; 
Schmidbaur et al., 1990). In this reaction an amino group from glutamate is transferred to 
oxaloacetate, giving aspartate and α-ketoglutarate. When glucose is scarce oxaloacetate will 
accumulate. This explains why the aspartate/glutamate ratio was found to be increased when 
the energy consumption was larger than the supply, such as during high neuronal activity 
(Szerb JC, 1988) and hypoglycemia (Gundersen et al., 2001) (ﬁg 2). 
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This means that glutamate formed through the glutaminase reaction should be a precursor 
of asparatate, but direct evidence for this was lacking. Moreover, whether glutaminase 
played a main role for the intraterminal production of glutamate and whether this applied to 
all excitatory terminals was not known. Opposite the the situation for glutamate-glutamine 
shuttle between neurons and astrocytes, evidence for a similar GABA-glutamine shuttle 
involving the glutaminase reaction in inhibitory terminals was scarce, as it was thought that a 
large part of GABA was derived from uptake across the plasma membrane through the GABA 
transporters (Bak et al., 2006).
 
(2) Concerning localization in excitatory nerve terminals electron microscopic studies 
showed inconsistent results. Even though several studies showed that aspartate was 
present in excitatory nerve terminals (Merighi et al., 1991; Tracey et al., 1991; Van den 
Pol, 1991; Usami and Ottersen, 1996, Gundersen, et al 1998, 2001), other studies found 
no evidence of such presence (Maxwell et al., 1990; Zhang et al., 1990; Ji et al., 1991; 
Montero, 1994; Larsson et al., 2001). It may be various reasons for this; different antibodies, 
different preparation procedures, varying concentration of aspartate in different neural 
pathways and the possibility that aspartate is not a transmitter in some of the terminals 
studied. The concentration of free aspartate in nervous tissue is signiﬁcantly lower than 
for glutamate (about 1/5), and balances on the limit of detection with electron microscopic 
immunocytochemical techniques. Hypoglycemia in the brain increases the amount of 
aspartate, and varying glucose concentration in the animals could have been a reason for the 
different ﬁndings (Gundersen, 2001).
The question of whether aspartate had access to synaptic vesicles was unresolved. 
Immunogold cytochemistry had given evidence that aspartate was located in excitatory 
synaptic vesicles (Gundersen et al., 1998). However, most studies showed that aspartate 
was not taken up into preparations of isolated synaptic vesicles (for review, see Fykse and 
Fonnum, 1996). In addition, the vesicular glutamate transporters did not seem to transport 
aspartate (Fremeau et al., 2004). Thus, further investigations of the uptake of asparatate in 
synaptic vesicles would throw important light on the transmitter status of aspartate.
Oxaloacetate
Citrate
Malate
Succinate
Krebs’
cycle
Acetyl-Coa
Pyruvate
Glucose
α-Ketoglutarate
Glutamate
Aspartate
energy
energyenergy
energy
GDH/AAT
AAT
Oxaloacetate
Citrate
Malate
Succinate
Krebs’
cycle
Acetyl-Coa
Pyruvate
Glucose
α-Ketoglutarate
Glutamate
Aspartate
energy
energyenergy
energy
Fig 2: The ﬂux of aspartate and glutamate through the Krebs’ cycle in normal (left) and 
hypoglycemic(right) situations. 
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Despite the negative results from the synaptic vesicle uptake studies, several investigations 
had showed that aspartate was released from depolarized nerve endings in a manner consistent 
with exocytosis (e.g. Gundersen et al., 1991, 1998), but some found no evidence for such a 
release (Nicholls, 1989, 1993). Thus, there was no general agreement about how aspartate was 
released (Nicholls and Attwell, 1990). 
In particular, the observation of an exocytotic release of aspartate could be explained by the 
possibility that aspartate is released from the cytosol through the EAATs in exchange for 
glutamate released from synaptic vesicles. Thus, any manipulation that affects the release of 
glutamate would also affect the release of aspartate. 
Although the strongest evidence of nerve terminal aspartate localization was from excitatory 
treminals, some studies indicated the presence of aspartate also in inhibitory GABAergic 
terminals (Ottersen and Storm-Mathisen, 1985; Gundersen et al., 1991, 2001). Whether 
aspartate was released from this type of terminal and by which mechanism was unknown.
(3) Aspartate was known to have a selective effect on the NMDA receptor, without activating 
any of the other glutamate receptor types (Curras and Dingledine, 1992). This means that 
aspartate could partly have a different role than glutamate when released into the synaptic 
cleft. Increased levels of aspartate, will lead to a shift towards a stronger NMDA-receptor 
stimulation. There was evidence that aspartate was released in increased amounts in 
hypoglycemia (Sandberg et al., 1986; Gundersen et al. 2001) and during increased neuronal 
activity (Szerb, 1988). This could mean that aspartate was responsible for parts of the 
excitotoxic effect seen in pathological conditions. 
 (4) Like for glutamate, if aspartate was a transmitter, it would be essential to keep the 
extracellular levels low in order to achieve an efﬁcient signal transmission and to avoid 
excitotoxicity . This job was known to be done by the EAATs, all of which transport aspartate, 
both the D- and the L-form, with high afﬁnities (Danbolt, 2001).
Low afﬁnity aspartate/glutamate transport
Some studies had described a low afﬁnity uptake system for aspartate and glutamate (see 
Danbolt, 2001). However, a more detailed characterization of the low afﬁnity system was 
lacking. In particular, the identity of the transporters underlying the low afﬁnity uptake was 
unknown. Also there was no information about which cell type in the brain that harbored low 
afﬁnity uptake sites.
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QUESTIONS TO BE ANSWERED
1. Is aspartate a transmitter at excitatory synapses? 
Release through the EAATs?
Uptake of D-aspartate in synaptic vesicles? Synthesis, release and uptake of   
transmitter amino acids at central nervous synapses
2. Is aspartate a transmitter at inhibitory GABAergic synapses? 
Location in synaptic vesicles?
Exocytotic release?
Presence of postsynaptic NMDA receptors?
3. Is glutaminase important for formation of transmitter L-glutamate, L-aspartate and  
 GABA in nerve terminals? 
4. Are there other uptake mechanisms than the EAATs for removing excitatory amino 
 acids from the extracellular space? 
QUESTIONS TO BE ANSWERED
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METHODS
Brain slices 
By incubating fresh slices of rat brain in a 
solution equivalent to extracellular ﬂuid in the 
brain (Krebs’ solution), it is possible to study 
the effect of different exogenous interactions 
(transporter substrates, membrane depolarisation, 
transmitter precursors etc). The Krebs’ solution 
has approximately the same ion composition, 
glucose concentration, pH and osmolality as the 
cerebrospinal ﬂuid.
The brain was harvested from a decapitated rat, 
quickly cooled in ice cold Krebs’ solution and the 
part of interest, e.g. the hippocampus or cerebellum, 
dissected out and cut on ice with a tissue chopper in 
0.3 mm thick slices, before putting the slices in the 
incubator (ﬁg. 3).
During the incubation, the slices were submerged 
in continuously oxygenated Krebs’ solution at 
30˚ C on nylon grids in a beaker (ﬁg. 4). Before 
starting any manipulation of the slices, they were 
pre-incubated in normal Krebs’ solution for one 
hour. This pre-incubation is thought to let the cells 
recover after the preparation procedure. 
An elegant way to study transporter proteins 
in the cell membranes is to add a substrate of 
the transporter and then reveal the intracellular 
localization of the added substrate. To recognize 
the exogenous substances from the endogenous 
substances radioactive substances could be used, 
or as I did, use substrates which do not naturally 
occur in the brain, and then detect the exogenous 
substance with immunocytochemistry (see below). 
The use of brain slices has some limitations of which the problem with diffusion of molecules 
into the slice is important. The diffusion distance of a molecule is dependent on the size 
of molecule, the time allowed for diffusion (the distance is proportional to the square root 
of the time), the tortuosity of the tissue or whether the molecule can diffuse through lipid 
membranes. The size of themolecule is the factor which requires most attention. Small 
molecules, like glutamine and D-aspartate easily diffuse through the whole slice. Large 
molecules, like proteins diffuse only a very short distance into the slice and their effect can 
therefore only be studied on the slice surface. 
Fig 3: The set up for slice incubation
Fig 4: Hippocampal slices submerged in 
solution on a nylon grid. The inset shows the 
slice at higher magniﬁcation.
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Embedding the tissue for electron microscopy
In order to study the tissue in the electron microscope very thin (about 100 nm thickness) 
tissue sections must be cut (ultarthin sections). This can be achieved from tissue that has 
been embedded in plastic resin. In this project I have embedded the tissue in Lowicryl HM20 
at low temperatures (for detailed protocol, see Materials and Methods in Paper IV).  The 
advantage of this embedding method is that it gives a good preservation of antigenic sites 
in the tissue, which in turn gives a high immunocytochemical labelling intensity. Some 
of the matrial was embedded in Durcupan. This procedure is less demanding to perform 
than the Lowicryl embedding, as it does not require a freeze-substitution unit. However, 
Durcupan emdedded tissue shows lower immunocytochemical sensitivity, partly because the 
polymerisation step is done at high temperatures (56 °C). Ultrathin sections were cut on an 
ultramicrotome, mounted on nickle grids (300-500 mesh) and processed with the different 
antibodies according to an immunogold method (see below).
Perparing the tissue for light microscopy
After immersion ﬁxing the hippocampal slices, they were cryo-protected in sucrose (30%) and 
20 μm thick sections were cut on a freezing microtome. Then the sections were subjected to 
immunocytochemistry according to a three layer immunoperoxidase method (see below).
Immunocytochemistry
Immunocytochemistry with antibodies selectively recognizing amino acids is of great value 
when studying amino acid neurotransmitters. This method was originally described by Jon 
Storm-Mathisen in Nature in 1983 (First visualization of glutamate and GABA in neurons by 
immunocytochemistry). In this work glutamate and GABA were conjugated to bovin serum 
albumin (BSA) by glutaraldehyde and the antisera were raised by injecting these amino acid-
glutaraldehyde-BSA conjugates in rabbits. By use of these antisera it was for the ﬁrst time 
possible to immunocytochemically localize the transmitter amino acids in the brain. Since 
then this method has been the “state of art” method for morphologic identiﬁcation of amino 
acid transmitters in the brain. It should be noted that the antibodies used in this thesis have 
been raised using a mixture of glutar- and formaldehyde to conjugate the amino acids to BSA. 
The resulting polyclonal antibodies react to different epitopes of these conjugates. Thus, 
a prerequisite for optimal antibody labelling is to use the same glutar- and formaldehyde 
mixture as a tissue ﬁxative.
The ﬁrst localization studies of amino acids where mostly done with the light microscopic 
immunoperoxidase method (Storm-Mathisen et al., 1983, Ottersen and Storm-Mathisen, 
1984, 1985, Gundersen et al., 1991). This method is mostly used in a qualitative manner 
to decide if a tissue compartment contains the amino acids or not. The method could also 
give an impression of the relative concentration of the amino acid based on the intensity of 
the labelling, but this is most useful when comparing structures with large differences in 
amino acid concentrations (e.g. glutamate or aspartate in nerve terminals before and after a 
depolarization (Paper I and III)). 
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Most amino acid transmitters, like glutamate and aspartate, are besides being transmitters, 
building blocks of proteins and important in metabolic routes. These amino acids are present 
in all cells. Therefore, it could be difﬁcult to separate the transmitter pool of amino acids from 
the metabolic pool, and small changes in the transmitter pool after synaptic release could thus 
be masked.  However, the releasable pool of transmitter amino acids in the nerve terminal is 
packed in synaptic vesicles, in which it is located with a much higher concentration than in 
the metabolic pool of amino acids in the cytosol. Thus, the transmitter and metabolic pool 
of amino acids can be recognized by quantitative methods, such as the electron microscopic 
postembedding immunogold method. GABA has on the contrary a much more limited 
metabolic role. It acts to a large extent exclusively as a transmitter. The GABA-labelling is 
therefore not as widespread as the other amino acid transmitters, being localized mostly to 
inhibitory ﬁbers in the brain. In many cases we are therefore more dependent on quantitative 
studies for localizing transmitter glutamate than transmitter GABA.
Accurate quantitative studies can be performed with a postembedding electron microscopic 
immunogold procedure (Bergersen et al, 2008), as this method, contrary to preembedding 
methods, is practically independent on penetration of the antibodies into the tissue section. 
Another great advantage of using this method is that it gives a high lateral resolution, which 
is required for studying labeling in subcellular compartments. The lateral resolution of the 
immunogold method (i.e. the distance between the epitope and the centre of the immunogold 
particle - approximately 20-30 nm) is much higher than the preembedding electron 
microscopic peroxidase method, in which the distance between the epitope and the peroxidise 
precipitate can be several micrometers.
Using the immunogold method I have compared the concentration of the substance of 
interest in different tissue compartments or in the same compartment in slices that have been 
treated differently. This can be done by counting the number of gold particles in the actual 
tissue compartment, determine the area of the compartment (by using computer programs 
or stereological methods) and then calculate the density of the gold particles (number of 
gold particles/μm2). To make a comparison of gold particle densities for an antigen between 
different compartments the density should proportional to the concentration of the antigen 
ﬁxed in the tissue (see below). 
Speciﬁcity testing of antibodies against amino acids in light and electron 
microscopic immunocytochemistry 
Antibodies are capricious, and they require a great level of caution when used in 
immunocytochemical procedures. Cross-reactivities and unspesiﬁc labeling can occur, and it 
is necessary with careful speciﬁcity testing. In quantitative studies it is also necessary to test 
that the antibody labeling of the amino acid is approximately proportional to the amino acid 
concentration in the tissue. 
If one works with tissue labeling of proteins, the most thorough and ultimate speciﬁcity test of 
the antibodies is to use tissue from an animal in which the protein in question is knocked out. 
Another possibility is to test the antibodies on cultured cells, which either express or do not 
express the particular protein (Bergersen et al., 2001). None of these tests are usually possible 
on amino acid antibodies. Most amino acids have several synthetic pathways, which cannot 
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be knocked out. An important exception is when working with labeling of exogenous amino 
acids that accumulate in tissues not endogenously containing the amino acid, like D-aspartate 
in the hippocampus (see below; Paper IV). 
A B
Antibody testing on tissues lacking the 
antigen
D-aspartate has a very low endogenous 
concentration in the forebrain, including the 
hippocampus (Gundersen et al., 1993), and 
is transported by the excitatory amino acids 
transporters in the same manner as L-glutamate 
and L-aspartate (Danbolt, 2001). I studied 
the glutamate/aspartate uptake in the brain by 
adding exogenous D-aspartate to the slices. 
Since D-aspartate is slowly metabolized in 
the forebrain (Davies and Johnston, 1975) 
it is “trapped” within the compartment in 
which it was taken up. Thus, it is possible 
to detect the localization of D-aspartate by 
using immunocytochemistry with antibodies 
recognizing the amino acid. Such a D-aspartate 
uptake assay is therefore well suited for 
studying uptake of excitatory amino acids in the 
brain (Gundersen et al., 1993, 1996).
When I labelled sections from hippocampal 
slices not incubated in D-aspartate with the 
402 D-aspartate antiserum there was no visible 
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Fig 6: A. The bars indicate the difference in 
gold particle density (average number of gold 
particles/μm2 ±SD) between sections from 
slices incubated in D-aspartate and those 
from slices not incubated in D-aspartate. 
B. Electron micrographs show D-aspartate 
immunogold labeling of two nerve terminals 
from a slice incubated in D-aspartate (a) and 
a slice not incubated in D-aspartate (b) (from 
work performed in Paper IV).
Fig 5: Sections from the work described in Paper IV. Section in A is from a hippocampal slice 
incubated in 0.5 mM D-aspartate in 15 min. Section in B underwent the same treatment as A, except 
that D-aspartate was not added to the incubation medium. Both are labeled in the same experiment 
according to the immunoperoxidase protocol with the 402 antiserum against D-aspartate. Note the 
lack of speciﬁc labeling of the section in B (only the shadows of the hippocampal layers and some 
edge staining of the section can be seen).  
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D-aspartate labelling in the light microscope, whereas the D-aspartate treated slices showed 
signiﬁcant staining (ﬁg 5). In the electron microscope there was immunogold labelling 
particular in nerve terminals and astrocytes in the D-aspartate treated hippocampus, whereas 
the labelling in the non-D-aspartate exposed tissue was at background level (ﬁg 6). This 
indicates that the D-aspartate antiserum does not cross react with any molecule present in 
the forebrain, which also was conﬁrmed by speciﬁcity “spot testing” (see below). Thus, I 
conclude that the D-aspartate antiserum is highly speciﬁc. 
 
Absorbing the speciﬁc antibodies
A commonly used speciﬁcity test is to absorb the antibodies with the antigen prior to applying 
the antibodies in the immunocytochemical procedure. I made soluble glutar-and formaldehyde 
complexes of the amino acids in question, which were added to the antibody solution before 
performing the immunocytochemical procedure. This treatment blocked the speciﬁc binding 
site of the antibody. Thus, any remaining labeling should be due to unspeciﬁc binding. I used 
this test both in the light and electron microscopic immunocytochemical procedures. 
However, this test has a potential weak point. Our experience is that the binding site of 
one antibody could recognize more than one amino acid; the one that it were originally 
raised against, but also other amino acids, which may get a similar antigen structure when 
conjugated with aldehydes to albumin. This “incorrect” labeling will also disappear when the 
binding site is blocked. Therefore, this method could not be entirely trusted if used alone. The 
test is a good complement to the “spot test” (see below).  
I have used this “absorption method” in all my immunhistochemistry work. In ﬁg 7 the 
method is applied for the antibodies against L-glutamate and L-aspartate.
Immunoperoxidase labelling Antisera blocked by the antigen
L-glutamate
L-aspartate
Fig 7: Light micrographs 
of immunoperoxidase 
labeled hippocampal 
slices (from work done 
in Paper I and III). The 
slices in the left column 
were treated according 
to the immunoperoxidase 
procedure with 
antisera raised against 
L-glutamate and L-
aspartate. The slices in 
the right column were 
treated in the same 
manner, except that 
the speciﬁc antisera 
were absorbed with the 
respective aldehyde 
treated amino acid (0.3 
mM). 
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Cross reactivity tests 
In most cases, working with amino acid antibodies, the most important test are those 
involving conjugates resembeling the antigens.
The light microscopic “spot test”
In my test system I ﬁxed L-glutamate, L-aspartate, glutamine and D-aspartate to brain 
proteins by formaldehyde and glutaraldehyde, forming amino acid – protein conjugates. The 
amino acid conjugates were spotted on a small piece of cellulose nitrate-acetate ﬁlter paper 
by a micro pipette. This spot test was performed along with each set of immunperoxidase 
experiments. For practical reasons only the four most relevant antigens were tested for each 
antiserum. One spot, containing ﬁxed brain macromolecules without any amino acids, were 
also added (named “none”). However, all our antisera have previously been tested against 
more than 40 small molecules known to be abundantly present in the brain (Ottersen, 1986). 
While working with Paper I, II and III I tested the following antisera: 607 L-glutamate 
(dilution 1:5000), 435 L-aspartate (dilution 1:2000) and 990 GABA (dilution 1:1000) (these 
antisera have also been previously characterized in Gundersen et al., 1998, 2001). The 
402 D-aspartate antiserum (dilution 1:500) was tested while working with Paper IV (these 
antibodies have been extensively tested in Gundersen et al. (1993). All antibodies tested (607 
L-glutamate, 435 L-aspartate, 990 GABA and 482 D-aspartate) were highly speciﬁc. All spot 
tests showed only one labeled spot (the one that contained the amino acid against which the 
antiserum was raised), except the spots stained by the L-aspartate antiserum, which showed 
a slight cross reaction with D-aspartate. However, this does not result in any cross-labelling 
L-asp
L-glu
None
L-gln D-asp
A B C D 
Fig 8: “Spot test”. A, Figure showing the antigens of each “spot”. 
The quarto pieces of paper where labelled with antisera against L-
aspartate (B), L-glutamate (C) and D-asparate (D). 
in the tissue sections since 
the brain regions studied 
in this thesis contain only 
trace amounts of D-aspartate 
(Hashimoto et al., 1995). In 
ﬁg 8 results of staining the 
spots with the L-aspartate, 
L-glutamate and D-aspartate 
is given as examples of the 
spot tests.  
Electron microscopic speciﬁcity test
The electron microscopic speciﬁcity test is in principle equal to the “spot test”. The antibodies 
are tested against different structurally related amino acids, which occur in the brain at high 
levels (see Ottersen, 1987). 
In our electron microscopic test system, the amino acid-glutaraldehyde/formaldehyde-brain 
protein conjugates (containing L-aspartate, L-glutamate, GABA, glutamine, taurine, glycine 
and ﬁxed brain proteins without any amino acid (“none”)) were mounted in layers with 
sections from rat brain between (Ottersen, 1989b; ﬁg 9). The amino acid concentration in the 
conjugates is about 100 mM (Ottersen, 1987).  This “sandwich” was embedded in Durcupan, 
and ultrathin sections were cut on an ultratome. The ultrathin sections were subjected to the 
postembedding immunogold method along with the ultrathin tissue sections described in 
Paper I, II and III. In Paper IV the 402 D-aspartate antiserum was tested in the same way, but 
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the “sandwich” contained a different battery of amino acid conjugates (see Gundersen et al., 
1993, 1995, 1996).
Results of labeling with the L-aspartate antiserum are given as an example of speciﬁcity 
testing using the electron microscopic test system (ﬁg 9, from work conducted in Paper III). 
The GABA and L-glutamate antisera have the similar speciﬁcity (Paper I, II and III). The 
density of immunogold particles over the L-aspartate conjugate produced by the L-aspartate 
antiserum (dilution 1:50) was very much higher than the densities over the other amino acid 
conjugates. From this I conclude that the L-aspartate antiserum is speciﬁc when tested in the 
electron microscopic test system (cf. the spot test above). 
Estimation of the relationship between gold particle density and antigen 
concentration
The conjugates could also be used to test the relationship between the gold particle density 
and the concentration of the ﬁxed amino acid. In this test the conjugates do not contain 
different amino acids, but different concentration of the same amino acid. All our antibodies 
tested till now have shown a close to linear relationship between the density of immunogold 
particles over the test conjugates and the amino acid concentration ﬁxed in the conjugates (see 
Ottersen, 1989a). Below I describe the linearity test of the L-aspartate antiserum. Such a test 
was performed in Paper I, II and III for the 435 L-aspartate antiserum (see Gundersen et al., 
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Fig 9: A: Immunogold labeling with the antiserum against L-aspartate. The bars show the gold 
particle density (average number of gold particles/μm2±SD) over conjugates of amino acids ﬁxed to 
brain macromolecules. B: Electron micrographs of the immunogold labeled conjugates.
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1998, 2001 for previous tests).  Similar tests have also been performed with the 990 GABA 
antiserum (Paper II) and previously with the 607 L-glutamate antiserum (Ericson et al., 1995; 
Gundersen et al., 1998) and 402 D-aspartate antiserum (Gundersen et al., 1995).
Conjugates where the L-aspartate concentrations have been estimated to be about 0, 0.04, 
0.1, 0.3, 1.0, 3.0, 9.0 and 27.0 mM were put together in layers with sections of brain tissue 
as spacers between. The stack was embedded in Durcupan, ultrathin sections were cut and 
processed with the 435 L-aspartate antiserum according to the immunogold method. 
The results for the L-aspartate antibodies are very similar to those previously obtained for 
glutamate antbodies (Ottersen, 1989a; Bramham, 1990). The slope is almost linear at antigen 
concentrations between 3-30 mM (ﬁg 10). Nerve terminals in the brain contain L-aspartate 
within this concentration range (Paper II; Gundersen et al., 1998). Thus, when studying the 
L-aspartate content in nerve terminals by immunocytochemistry (Paper I, II, III) the immuno-
signal is positively correlated with the concentration of the amino acid.
In Paper I and II I used such graphs, in combination with the immunogold particle density 
in tissue compartments, to estimate the amino acid concentration ﬁxed in the tissue. 
However, some precautions must be taken when doing this. Mostly I used tissue which has 
been embedded in Lowicryl, whereas the graded test sections were embedded in Durcupan 
(Ottersen, 1989b). Thus, the tissue sections mostly give a stronger immunogold signal than 
the test sections. Second, a certain proportion (about 30-50 %) of the amino acids are lost 
during the ﬁxation procedure (Storm-Mathisen and Ottersen, 1990), meaning that one must do 
an approximation in order to estimate the concentration of the free amino acid in the tissue.  
This test could also be used to get a rough estimation of the sensitivity of the labeling; i.e. 
which amino acid concentration that is necessary to get a signal signiﬁcantly higher than 
background. The gold particle density (the number of L-aspartate immunogold paricles/μm2) 
in the example in ﬁg 10 was higher than the background (0 mM L-aspartate) at 0.3 mM L-
aspartate. The average tissue concentration of L-aspartate is about 2 mM (the L-glutamate 
concentration is 5 times higher) (Nadler et al., 1978), whereas the concentration in nerve 
terminals is higher (the concentration of ﬁxed L-aspartate in nerve terminals is about 3-4 
mM (Paper II; Gundersen et al., 1998), giving a concentration of about 6-8 mM of free L-
asparatate in the terminals). The sensitivity of the L-asparate antibodies is in other words 
sufﬁcient for transmitter studies. 
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Fig 10: A. Gold particle densities signaling L-aspartate (number of gold particles/μm2) over 
conjugates with different L-aspartate concentrations. a-f are electron micrographs of the graded L-
aspartate conjugates showing that the density of the gold particle labeling increases with increased 
amino acid concentration in the conjugates. B shows the relationship between the ﬁxed antigen (L-
aspartate) and the gold particle densities. The detection limit of the L-aspartate immuogold method is 
about 0.3 mM.
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SUMMARY OF RESULTS
Paper I
There are convincing data substantiating that L-aspartate is released by exocytotosis from 
excitatory nerve terminals. The release, which is triggered by depolarization, is dependent 
on calcium and the SNARE proteins. However, it has been argued that the same ﬁndings 
could be seen if L-aspartate was released by heteroexchange against exocytotically released 
glutamate through the excitatory amino acid transporters (EAATs). To test this theory we 
blocked the EAATs in depolarized hippocampal slices. The release of L-aspartate from 
excitatory terminals was only weakly affected by this blocking, further adding to the evidence 
of asprtate exocytosis from these terminals. 
A major argument against exocytotic release of aspartate was until recently that no vesicular 
aspartate transporter was described. The vesicular glutamate transporters (vGLUTs) do neither 
transport L- nor D-aspartate. In the present paper we showed that exogenously D-aspartate 
added to hippocampal slices is taken up and stored inside vesicles. There is no known route 
in the hippocampal neurons which can metabolize and synthesize D-aspartate, meaning that 
the exogenous added D-aspartate must have been transported into the vesicles by an aspartate 
transporter. This vesicular transporter carries probably both D- and L-aspartate. Our results ﬁt 
with the recent ﬁnding of a vesicular aspartate transporter in hippocampal synaptic vesicles.
Paper II
There are strong evidence that aspartate could act as a transmitter at excitatory synapses. 
Previous immunocytochemical studies link aspartate also to GABAergic neurons. In the 
present study we used the immunogold method to detect aspartate and GABA in hippocampal 
slices.  We could show that under resting conditions the excitatory transmitter aspartate was 
present in synaptic vesicles in GABAergic terminals, and that aspartate and GABA were 
depleted from the same terminals during potassium induced depolarization. In the absence of 
calcium or in the presence of tetanus toxin (both preventing exocytosis) the depletion of both 
GABA and aspartate was blocked.
Since the NMDA-receptor is the only receptor activated by aspartate, we investigated if 
this receptor was located in the GABAergig synapses. By immunogold double labeling, 
we showed that NMDA receptors were present in GABAergic synapses. We propose that 
exocytotically released aspartate could play a physiological role in the GABAergic, inhibitory 
synapses.
Paper III
An important part of the recirculation of glutamate between nerve terminals and astrocytes is 
thought to be played by the enzyme phosphate activated glutaminase, which turns glutamine 
into glutamate in the terminals. 
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In this paper we inactivated glutaminase in cerebellar slices with the use of DON. By this 
we showed a signiﬁcant reduction in glutamate, aspartate and GABA in terminals during 
membrane depolarization in spite of the presence of glutamine, which is a substrate of 
glutaminase. This means that the synthesis of glutamate, aspartate and GABA is dependent on 
the glutaminase reaction. 
Paper IV
By incubating hippocampal slices with millimolar concentrations the glutamate analogue 
D-aspartate and pharmacologically blocking the high afﬁnity glutamate transporters (excita-
tory amino acid transporters – EAATs) we showed that low afﬁnity glutamate transporters 
are present in astrocytes in the hippocampus. D-aspartate uptake activity was detected by 
D-aspartate immunocytochemistry. When incubating hippocampal slices in a low concentra-
tion of D-aspartate (0.01 mM), D-aspartate was taken up into nerve terminals and astrocytes. 
When adding PMB-TBOA, a potent EAAT blocker, no sign of D-aspartate was evident. When 
the slices were incubated with PMB-TBOA during increased D-aspartate concentrations (0.5 
and 1.0 mM) the nerve terminal uptake was blocked, but a signiﬁcant uptake remained in the 
astrocytes. We conclude that this PMB-TBOA insensitive astrocyte uptake of D-aspartate rep-
resents a low afﬁnity uptake, which is only active when the levels of extracellular glutamate 
and aspartate are raised to millimolar concentrations.
Further characterization of the PMB-TBOA insensitive uptake showed that removing the 
sodium ions in the incubation solution entirely blocked the uptake. This indicates that 
the transporter responsible for the PMB-TBOA insensitive uptake in astrocytes is sodium 
dependent. When adding succinate, in addition to PMB-TBOA, to the D-aspartate exposed 
slices the low afﬁnity transport was signiﬁcantly reduced. These characteristics ﬁt with 
the idea that a Na+/dicarboxylate cotransporter is located in the astrocyte membrane and 
contributing to the observed low afﬁnity aspartate/glutamate uptake. 
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DISCUSSION
Release of aspartate from nerve terminals
Aspartate is present in nerve terminals and is released during depolarization (see 
Introduction). However, there has been dissension about the actual release mechanisms. The 
conﬁrmation of this is a crucial point for determining its transmitter status. There are at two 
possible release mechanisms:
A) Through exocytosis
B) Through a channel or a transport protein 
The following discussion will mainly be based on the role of aspartate at excitatory synapses. 
However, the similar arguments hold true for the role of aspartate at inhibitory synapses (see 
below).
A) There is plenty of evidence indicating that release of aspartate through exocytosis is 
important. First, immunocytochemistry of hippocampal slices has shown that aspartate 
is localized in and released from synaptic vesicles in excitatory (Gundersen et al., 1998; 
Yatsushiro et al., 1997) and inhibitory terminals (Paper II). In addition, there are convincing 
biochemical data showing Ca2+dependent release of aspartate in brain slices and in the 
intact brain (see Gundersen and Storm-Mathisen, 2000). In contrast, there have been some 
conﬂicting data concerning the Ca2+-dependency of aspartate release in synaptosomes (see 
Nicholls and Attwell, 1990). However, evidence have accumulated during the last years 
that aspartate is released by exocytosis also from synaptosomes (e.g. McMahon et al., 1992; 
Bradford and Nadler, 2004; Wang and Nadler, 2007).  Importantly, aspartate release is 
inhibited by clostridium toxins (McMahon et al., 1992; Gundersen et al., 1991; Wang and 
Nadler, 2007), of which tetanus toxin degrades synaptobrevin and botulinum toxin cleaves 
several proteins of the SNARE complex (Schiavo et al, 1992).  These proteins are necessary 
for the vesicle fusion with the cell membrane. 
There has for a long time been one important missing link in the theory of exocytotic 
release of aspartate. How does aspartate get into the vesicles? Several studies have tried to 
demonstrate a vesicular aspartate uptake, most of them by measuring inhibition of vesicular 
glutamate uptake. Aspartate did not inhibit the glutamate uptake into isolated synaptic vesicles 
from the whole brain (Naito and Ueda, 1983, 1985; Maycox et al., 1988; Tabb and Ueda, 
1991; Fykse et al., 1992; Burger et al., 1989). Thus, the conclusion was drawn that aspartate 
is not taken up in vesicles. However, one study reported that aspartate is transported into 
synaptic vesicles (Fleck et al., 2001a). The fact that the vesicular glutamate transporters 
(vGLUTs) exclusively seem to transport glutamate (Fremeau et al., 2004), as well as that the 
vesicle uptake of aspartate and glutamate is not inhibited by the other, and that their uptake 
afﬁnities are somewhat different (Fleck et al., 2001a), supports the possibility that aspartate 
is taken up into synaptic vesicles by another transporter than the vGLUTs. Recently, this 
assumption proved to be correct. Miyaji et al. (2008) demonstrated that a H+/sialic acid co-
transporter pumps aspartate into synaptic vesicles. They have renamed it vesicular excitatory 
amino acid transporter (VEAT). In adition to sialic acid, VEAT transports L-aspartate as 
well as L-glutamate, and D,L-threo-hydroxy aspartate (THA) (see Fleck et al., 2001b). The 
localization of VEAT in the intact brain is not yet established, but the authors have shown that 
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the transporter is present in synaptic vesicles isolated from the hippocampus as well as from 
pinealocytes (the latter cells store and release both aspartate and glutamate (Yatsushiro et al., 
1997)).
As VEAT transports the D-aspartate analogue THA (Miyaji et al., 2008) it may be envisaged 
that it also transports D-aspartate. This would ﬁt nicely with the D-aspartate immunogold data 
presented in Paper I and with data showing D-aspartate uptake in isolated synaptic vesicles 
(Fleck et al., 2001a), as well as with the fact that D-aspartate can be released by exocytosis 
after it has been preloaded into different brain tissue preparations (Malthe-Sørenssen et al., 
1979; Drejer et al., 1983; Potashner, 1983; Minc-Golomb et al., 1987; Cousin et al., 1997; 
Cousin and Nicholls, 1997; Rousseau et al., 2005; Raiteri et al., 2007). Furthermore, THA 
reduces the release of L-aspartate, probably by an effect on the vesicular aspartate uptake 
system, but has no effect on the L-glutamate release (Fleck et al., 2001a). 
One study (Bradford and Nadler, 2004) has shown that aspartate release, in contrast to 
glutamate release, is not blocked by baﬁlomycin. Baﬁlomycin is a bacterial toxin (from 
Streptomyces griseus) which speciﬁcally inhibits the vesicular H+-ATPase. Glutamate 
transport through the vGLUTs is driven by the electrical component set up by the H+ 
electrochemical gradient over the vesicular membrane. The vesicular H+-ATPase creates 
this driving force. However, the results of Bradford and Nadler (2004) do not ﬁt with the 
properties of VEAT, which like the vGLUTs, is driven by the electrochemical gradient across 
the vesicle membrane ((Miyaji et al., 2008). It should be noted that the data in Bradford and 
Nadler (2004) indicated that the release of aspartate was much less sensitive to clostridium 
toxins than that of glutamate. However, in a later publication Victor Nadler shows that after 
electroporation tetanus toxin does indeed inhibit the release of aspartate (Wang and Nadler, 
2007), suggesting that the former results were due to limited access of tetanus toxin (and 
perhaps of baﬁlomycin) to the nerve terminals.
B) There is an alternative hypothesis of aspartate release from nerve endings; release through 
a protein transporter. Because of the strong evidence of a Ca2+-dependent and clostridium 
toxin sensitive release, a simple one-way transport (e.g. through reversal of EAATs) 
responsible for the total release of aspartate is unlikely. However, aspartate release could be 
inhibited by means that block exocytosis if it occurs secondary to synaptic glutamate release. 
When glutamate is released, the extracellular concentration of glutamate would temporarily 
be very high. This could trigger a heteroexchange with cytosolic aspartate through the EAATs 
located in the nerve terminal membranes (Gundersen et al., 1993; Furness et al., 2008; Paper 
IV). 
There are several pieces of data that weaken the heteroexchange theory. First, immunogold 
cytochemistry show that aspartate is concentrated in synaptic vesicles rather than in the 
cytosol (Paper II, Gundersen et al., 1998). In Paper I we have blocked the EAATs with the 
potent blocker PMB-TBOA. If aspartate was dependent on the EAATs for release (through 
heteroexchange) the release should be terminated by this blocker. However, we observed 
that signiﬁcant amounts of aspartate were released in nerve terminals during membrane 
depolarization, even if the EAATs were blocked. In Paper I we discovered that 30-36% of 
aspartate and glutamate released from the excitatory terminals could be blocked by blocking 
the EAATs. This probably represents release through reversal of the EAATs (during the high 
K+-conditions) and ﬁts well with earlier ﬁndings, which have shown that the residual release 
of aspratate and glutamate during blocking of exocytose makes up about 30-40 % of the 
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excocytotic release (Gundersen et al., 1998). 
There are, in my opinion, two possible 
mechanisms for vesicular aspartate accumulation. 
Glutamate could be transformed to aspartate 
inside the vesicles. However, this is probably 
the least probable explanation. Firstly, aspartate 
aminotransferase is found in mitochondria 
(McKenna et al., 2000), but there is no evidence 
of any vesicular localization. Secondly, as 
discussed above exogenous D-aspartate 
accumulates in synaptic vesicles (Paper I). Even 
though the possibility exists that L-aspartate 
could be created from L-glutamate in the vesicles, 
conversion of L-aspartate to D-aspartate is highly 
unlikely, as it would require an intrasynaptic 
racemase. The activity of D-aspartate racemase 
is very low in the adult forebrain (Davies and 
Johnston, 1975). 
I therefore consider the ﬁrst possible mechanism 
for vesicular aspartate accumulation for the most 
probable; namely through a vesicular aspartate 
transporter. Indeed, the recent identiﬁcation of 
VEAT (Miyaji et al., 2008) greatly supports this notion, but more work has to be done to settle 
this (particularly thorough localization studies to see if all proposed aspartergic terminals in 
the brain contain VEAT). 
Thus, taking an excitatory synapse as an example (ﬁg 11), glutamate is formed from 
glutamine through phosphate activated glutaminase (see below). Then aspartate is produced 
from glutamate via aspartate aminotransferase (AAT). The vGLUTs exchange glutamate 
against protons, while aspartate is transported by another vesicular transporter, probably 
VEAT. The aspartate uptake is also dependent on H+-ATPase if VEAT is the dominant 
vesicular aspartate transporter. In ﬁg 11 the two transporters are indicated in the same vesicle 
for simplicity.
The synthesis of glutamate, aspartate and GABA
Laake et al. (1999) showed low levels of phosphate activated glutaminase (PAG) in the 
glutamatergic parallel ﬁbers in the cerebellum. They observed that the parallel ﬁber terminals 
contained similar PAG levels as GABAergic terminals. These levels were only about 20 % of 
the PAG level seen in the cerebellar mossy ﬁbers. The low PAG levels in the glutamatergic 
parallel ﬁber terminals (and the GABA terminals) correspond poorly with the theory of 
recirculation of glutamate (and GABA) between nerve terminals and astrocytes, where PAG is 
an important step. 
However, in Paper III we found that glutaminase is necessary to produce releasable glutamate 
Fig 11: Cartoon showing the mechanisms for 
exocytotic release of glutamate and aspartate. 
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from glutamine during synaptic activity. This seems like a contradiction to the ﬁndings of 
Laake et al. (1999), who used antibodies against the kidney type of PAG (see below), and 
the immunogold method to detect and quantify the levels of the enzyme. However, they 
determined the relative amount of the enzyme, not the glutaminase activity. In Paper III we 
studied the activity of the enzyme by observing the increased level of the product (glutamate) 
when the substrate (glutamine) was added and then the absence of the product when the 
enzyme was blocked. 
There could be several reasons why the parallel ﬁbers have lower levels of the kidney PAG 
than the mossy ﬁber terminals. As there is not necessarily any strict relation between the 
amount of enzyme and its activity it could be that the low density of PAG in the parallel ﬁber 
terminals has an activity high enough to sustain the glutamate levels during synaptic release. 
Moreover, it is possible that the parallel ﬁber terminals contain isoenzymes of glutaminase 
that were not recognized by the antibodies used by Laake et al. (1999). There are two 
established isoenzymes, the kidney and the liver type (Aledo et al, 2000). Laake et al (1999) 
used antibodies against the former type.
It should also be mentioned that the parallel ﬁber terminals are tightly ensheathed by 
Bergmann glial processes (Grosche et al., 2002), which contain EAAT1 (Lehre et al., 1995) 
that actively take up glutamate during synaptic transmission (Clark and Barbour, 1997; 
Takayasu et al., 2004). Interestingly, the glial processes around parallel ﬁbers contain much 
higher densities of EAAT1 than the processes around mossy ﬁber terminals (Chaudhry et al., 
1995). In addition, EAAT4 is located in Purkinje cell dendrites postsynaptic to the parallel 
ﬁber terminals (Dehnes et al., 1998), suggesting that most of the synaptically released 
glutamate at the parallel ﬁber synapse is taken up by other EAATs than those present on nerve 
terminals. This suggests that a minor fraction of the synaptically released glutamate enters 
the terminal by reuptake, and that the parallel ﬁber terminals are dependent on replenishment 
of transmitter glutamate via the glutamate-glutamine cycle and a glutaminase reaction in 
the terminals. This is in line with our ﬁnding that the parallel ﬁber terminals contain high 
glutaminase activities. In contrast, the astrocytic ensheathment of the mossy ﬁber synapse is 
less developed than that of the parallel ﬁber synapse (Peters et al., 1991). However, despite 
that little is known about glutamate transporters on nerve terminal plasma membranes in the 
cerebellum, it seems as if the mossy ﬁber terminals contain less uptake sites for glutamate 
than the parallel ﬁber terminals (Wiklund et al., 1982). In other words, even though there 
probably is more available glutamate around mossy than parallel ﬁber terminals, poor uptake 
capacity prevents the mossy ﬁber terminals to depend on a reuptake. This may explain why 
also mossy ﬁber terminals possess high levels of the glutaminase enzyme (Laake et al., 1999; 
Paper III). 
In Paper III we also showed that the release of aspartate from glutamatergic terminals in 
the molecular (parallel ﬁber terminals) and granule (mossy ﬁber terminals) layer of the 
cerebellum and that the release of GABA from inhibitory terminals is dependent on PAG. 
These results further support the notions that aspartate can be a transmitter at central synapses 
(Paper I, II) and that glutamine is an important precursor for releasable GABA. When 
working with Paper III we noticed PAG-dependent aspartate localized in inhibitory Golgi cell 
terminals in the granular cell layer. Such a presence of aspartate in inhibitory GABAergic 
terminals is in line with data presented in Paper II (also see Gundersen et al., 2001).
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Aspartate in inhibitory synapses
I have in this thesis argued for aspartate as an excitatory transmitter. It is substantial 
evidence that aspartate is present in and released from excitatory nerve terminals, probably 
by exocytosis. Paper II shows that aspartate is localized in and released by exocytosis from 
inhibitory nerve terminals along with GABA. The exocytotic co-release of aspartate and 
GABA, as well as of aspartate and glutamate, is in line with evidence that other fast acting 
neurotransmitters are co-released from synaptic vesicles: glycine and GABA (Jonas et al., 
1998), ATP and GABA (Jo and Schlichter, 1999) and glutamate and acetylcholine (Nishimaru 
et al., 2005) in spinal cord synapses; glutamate and GABA in mossy ﬁber synapses (Walker 
et al., 2001; Bergersen et al., 2003). Recently, Boulland et al. (2008) demonstrated that a 
vesicular glutamate transporter and the vesicular GABA transporter were both present in the 
same nerve terminal in the dentate gyrus of the hippocampus. 
There could, however, be alternative explanations of the exocytosis dependent depletion 
of aspartate from GABAergic synapses. Firstly, aspartate could be released by reversed 
transport through amino acid plasma membrane transporters during depolarization. However, 
this explanation is less likely as excitatory amino acid transporters (EAATs) seem not to be 
present in the membranes of GABAergic terminals (Gundersen et al., 1993). In addition, our 
observation that the aspartate release from GABA terminals is Ca2+-dependent and tetanus 
toxin sensitive speaks against release by reversed transport. However, we cannot strictly rule 
out the possibility that aspartate could be removed from the GABA-terminals in an indirect 
manner: Aspartate could be converted to glutamate by the enzyme aspartate aminotransferase. 
Glutamate is a precursor for GABA via a reaction catalyzed by glutamate decarboxylase. 
Therefore, it is possible that aspartate is consumed to meet the demand of releasable GABA. 
However, it seems like aspartate is mainly localized in vesicles, and is thus inaccessible for 
aspartate amino transeferase.
Aspartate has an effect exclusively on the NMDA type of glutamate receptors (Curras and 
Dingledine, 1992). This means that aspartate released at a glutamatergic synapse will lead to a 
relatively stronger activation of NMDA receptors compared to that of AMPA receptors. In the 
GABAergic synapses aspartate will be responsible alone for the NMDA receptor activation, 
which could serve as a tool for ﬁne regulation of the extent of excitatory and inhibitory input 
to a neuron. In this respect it should be noted that NMDA receptor activation could occur even 
if the Mg2+ block is not removed by concomitant depolarization of the synaptic membrane 
(Parri et al., 2001; Karadottir et al., 2005; Jourdain et al., 2007). Aspartergic NMDA receptor 
activation could be important for e.g. synaptic potentiation phenomena, such as long term 
potentiation. 
Uptake of excitatory amino acids from the extracellular space
In Paper IV we demonstrated that D-aspartate was transported into astrocytes by an EAAT-
independent low afﬁnity uptake system. The fact that the uptake was sodium dependent 
and reduced by succinate, suggests that a Na+/dicarboxylate cotransporter, which transports 
aspartate and glutamate with low afﬁnities (for review, see Markovich and Murer, 2004), is 
responsible for the observed D-aspartate uptake. Thus, in the following I call this D-aspartate 
uptake mediated by the dicarboxylate transporter “aspartate/glutamate uptake” (cf. the 
DISCUSSION
36
AT Holten 2008
substrate speciﬁcities for the EAATs (Danbolt et al., 2001)). As NaC3 has been shown to be 
present in cultured astrocytes (Fujita et al., 2005), I think that this transporter underlies the 
transport of aspartate/glutamate in our experiments. In the course of the work with Paper IV, 
we tried to localize NaC3 by immunocytochemistry, using a commercial antibody, but we did 
not succeed. We suspect that the antibodies were not of high enough sensitivity.
As succinate could not entirely block the observed D-aspartate accumulation, I should 
emphasize that there could be additional low afﬁnity aspartate/glutamate transporters 
mediating excitatory amino acid uptake in astrocytes.  Because we found that homocysteate 
also to a certain extent could inhibit the low afﬁnity aspartate/glutamate uptake such a 
transporter could belong to the ASC transporters (Budy et al., 2006).
Since the exctracellular aspartate/glutamate concentration must be around 0.5 mM to give 
an considerable inﬂux through NaC3 (Huang et al., 2000; Paper IV) a possible function of 
this low afﬁnity transport system could be to help regulating the uptake of excitatory amino 
acids after synaptic release, during which the concentration of aspartate/glutamate can rise to 
mM concentrations (Danbolt, 2001). Also in pathological conditions, where the extracellular 
concentrations of aspartate/glutamate are high, this low afﬁnity uptake system can be 
important (see below).
It has to be emphasized that the main function of NaC3 and the other dicarboxylate 
transporters is probably not uptake of excitatory amino acids, but transport of Krebs’ cycle 
intermediates (preferably dicarboxylates with four or ﬁve carbon chain length). Succinate 
is one of the high afﬁnity substrates of this transporter. The chemical structure of aspartate 
differs only from succinate by aspartate’s amino group. However, this one positively charged 
group gives a large reduction in afﬁnity (Huang et al.,2000; Wang et al.,2000; Burckhardt et 
al.,2005; Fujita et al.,2005). When NaC3 expressed in mammalian cell lines were tested for 
inhibition succinate transport, millimolar concentrations of aspartate and glutamate could 
signiﬁcantly inhibit succinate uptake by about 40 % and 20 %, respectively (Huang et al., 
2000; Wang et al., 2000). Thus when the concentrations are high it seems like NaC3 transports 
the excitatory amino acids quite efﬁciently. This ﬁts with the extensive low afﬁnity aspartate/
glutamate uptake observed in astrocytes in Paper IV.
The low afﬁnity uptake system seem to transport aspartate more efﬁciently than glutamate. 
Aspartate reduces succinate (Huang et al., 2000; Wang et al., 2000) and N-acetyl-L-aspartate 
(another high afﬁnity NAC3 substrate) (Fujita et al., 2005) uptake through NaC3 more 
efﬁciently than glutamate. Thus, NaC3 has a lower Km for aspartate then glutamate. This 
could be of importance during certain pathological conditions, since aspartate selectively 
activates the NMDA receptors, and could therefore at high concentrations give a relatively 
stronger contribution to excitotoxocity than glutamate. 
Pathological conditions
The above described aspartate exocytosis from excitatory and inhibitory nerve terminals 
and the low afﬁnity uptake system for excitatory amino acids could be involved in various 
pathological states in the brain.
DISCUSSION
37
Synthesis, release and uptake of transmitter amino acids at central nervous synapses
Aspartate seems to selectively activate NMDA receptors (Curras and Dingledine, 1992). In 
addition, the ratio of aspartate release to glutamate release increases during high neuronal 
stimulation (Szerb, 1988; Szerb and O’Regan, 1987) and when brain energy levels are low, 
such as during hypoglycemia (Gundersen et al., 2001). Thus, during these conditions the high 
release of aspartate may shift the activation of glutamate receptors towards higher NMDA 
receptor activation. An “overactivation” of NMDA receptors is detrimental to the brain and 
involved in the development of several disease states. 
Epilepsy
E.g. during status epilepticus it is shown that inhibition of hippocampal granule cells is lost. 
This loss can be annulled by NMDA receptor antagonists (Mazarati and Wasterlain, 1997). 
Thus, it could be that during epilepsy an increased NMDA receptor activation of granule 
cells, which can be mediated by an enhanced release of aspartate, could neutralize or even 
reverse the inhibitory GABA effect. Therefore, this could make inhibitory synapses excitatory 
and participate in the uncontrolled excitatory activity during epilepsy. Further adding to 
this notion is that it is known that mice genetically predetermined for epilepsy, but not yet 
experienced seizures, have a high release of aspartate (Flavin and Seyfried, 1994).
Brain ischemia
High extracellular excitatory amino acid concentrations cause massive stimulation of the 
glutamate receptors, particularly the NMDA receptors. This could lead to degeneration of 
neurons because of excessive calcium inﬂux through the activated receptors. This is called 
excitotoxicity (Olney, 1969), which is one of the main factors underlying the death of neurons 
during e.g brain ischemia (Mattson, 2003).
The brain contains huge amounts of putative toxic excitatory amino acids, which are trapped 
inside intracellular vesicular compartments by energy dependent processes. When the energy 
balance in the brain is broken down during ischemia, these excitatory amino acids represent 
a risk if they are released into the extracellular space. Also if the extracellular concentrations 
of aspartate/glutamate are allowed to build up during normal synaptic transmission, they 
may represent a potential danger to the neurons. Thus, the brain balances between excitatory 
transmission and excitotoxicity. However, the brain has evolved protective systems, e.g. 
represented by the EAATs, against the harmful effects of aspartate and glutamate. This can 
be demonstrated by adding exogenous glutamate receptor agonists to the brain. For example, 
adding of kainate, which is a poor substrate of the EAATs, to the striatum will lead to 
extensive neuronal death (Coyle and Schwarcz, 1976; Obrenovitch et al., 2000). However, 
simple adding of glutamate, which will be taken up by the EAATs, requires much higher 
concentrations to create cell death, and the affected region will be much smaller. In a study by 
Mangano and Schwarz (1983) high glutamate concentrations (in the molar range) were added 
to the rat striatum repeatedly every 12 hour in 14 days, but only a minor degeneration was 
seen. In contrast, in pure neuronal cultures, where astrocytes containing efﬁcient protective 
glutamate uptake systems are lacking, a much smaller concentration of glutamate will kill the 
neurons (50-100μM (Choi et al., 1987)). If the neuronal EAATs are blocked in such cultures, 
then glutamate concentrations in the lower μM range are sufﬁcient to cause neuronal death 
(Frandsen and Schouseboe, 1990). Moreover, in conditions where the uptake of excitatory 
amino acids is compromised, such as during lack of energy, excitatory amino acids are 
severely toxic to the neurons (Novelli et al., 1988). 
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During physiological conditions, in which extracellular glutamate and aspartate mainly 
comes from synaptic release, the EAATs comprise the most important protective system for 
removing the amino aids from the extracellular space. During pathological conditions, in 
which there is a massive efﬂux of excitatory amino acids (a situation mimicked by Mangano 
and Schwarz (1983)) the low afﬁnity uptake system for excitatory amino acids (Paper IV) will 
probably also be important. The low afﬁnity system has Km values of about 1 mM (Logan 
et al., 1972; for NaC3 kinetics, see Huang et al., 2000), whereas the Km values of the high 
afﬁnity system (EAATs) are in lower micromolar range (Danbolt, 2001). The high afﬁnity 
system would probably not be able to increase its transport activity when the extracellular 
glutamate approaches millimolar concentration, because it is saturated at much lower 
concentrations. Low afﬁnity uptake is far from saturated, and can take a greater part in the 
removal of extracellular glutamate during conditions with elevated glutamate concentrations. 
During brain ischemia a deﬁcient Na+/K+-ATPase-function could lead to depolarization of 
cells of the brain. Depolarization and increased intracellular Ca2+ concentration lead to a 
massive exocytosis of aspartate/glutamate and eventually to reversal of excitatory amino 
acid transporters. Glutamate in the astrocytes will not be transformed to glutamine, because 
glutamine syntethase requires ATP. Thus, glutamate will accumulate in the astrocytes, 
which in turn will lead to an increased driving force for reversal of glial EAATs, or at least 
make the inward transport less efﬁcient. In turn this will lead to further increases in the 
extracellular concentrations of aspartate and glutamate. In Paper IV we detected that the low 
afﬁnity system transports excitatory amino acids at concentration down to 50 μM. As it also 
efﬁciently transports aspartate/glutamate at millimolar concentrations, this system could 
therefore contribute to the prevention of excitotoxicity during brain ischemia.
Such a role will require that the low afﬁnity transporters, including the Na+/dicarboxylate 
transporters, can take up excitatory amino acids during ischemic conditions. Net uptake 
through the high afﬁnity excitatory amino acid uptake system is less efﬁcient when the ion 
gradients across the plasma membrane are reduced. At least the high afﬁnity transport can 
reverse during ischemia and massive depolarization (Rossi et al., 2000; Allen et al., 2004). 
The transport through NaC3 is, like the EAATs, driven by an inward sodium co-transport 
(three Na+ ions pr decarboxylate molecule). During membrane depolarization this uptake 
decreases because of reduced transmembrane potential difference (tested for succinate uptake, 
not for aspartate or glutamate)(Wang et al., 2000). However, in intact tissue it seems like the 
astrocytes can accumulate aspartate/glutamate through the low afﬁnity Na+/dicarboxylate 
transport system, even if their membranes are depolarized by high K+ concentrations (Paper 
IV). The low afﬁnity transporters could mediate this inward transport of aspartate/glutamate 
through a Na+ dependent net uptake, or if these transporters, like the EAATs convey 
heteroexchange (see Furness et al., 2008), through a Na+ independent  heteroexchange with 
intracellular succinate. 
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CONCLUSIONS
1. Aspartate is a transmitter at excitatory synapses: 
The release of L-aspartate from excitatory nerve terminals is mainly by way of  
exocytosis, only a minor fraction escapes through reversal of the EAATs.
D-aspartate is transported into excitatory synaptic vesicles
2. Aspartate is a transmitter at GABAergic synapses: 
Aspartate is present over synaptic vesicles and depleted by exocytosis. 
NMDA-reseptors are present in postsynaptic dendrites. 
3. During synaptic transmitter release the nerve terminal content of glutamate, as well as 
 that of aspartate and GABA, is dependent on synthesis from glutamine through the 
 enzyme glutaminase.
4. During episodes of raised extracellular levels of aspartate and glutamate, the 
 low afﬁnity transport system transports the excitatory amino acid into astrocytes. 
 Na+/dicarboxylate cotransporters are probably important transporters in this system.   
 Thus, the EAATs are probably not the only plasma membrane transporters important 
 for clearing aspartate and glutamate from the extracellular space.
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Aspartate (blue) and glutamate (red) or aspartate (blue) and GABA (yellow) are released from 
glutamatergic and GABAergic nerve terminals (Paper I, II and III), respectively. The co-release of 
aspartate and glutamate are shown to occur by exocytosis (1), but release through the excitatory 
amino acid transporters (2) also contributes (Paper I). GABA and aspartate are released via 
exocytosis from GABAergic terminals (1) (Paper II). After release aspartate and glutamate are 
transported into surrounding astrocytes (Paper I, III) by excitatory amino acid transporters (3) and 
low afﬁnity aspartate and glutamate transporters (4) (Paper IV), whereas GABA is transported by 
GABA transporters (5). In astrocytes glutamate is converted to glutamine by glutamine synthetase 
(6). Aspartate and GABA are ﬁrst converted to glutamate, which in turn forms glutamine through the 
glutamine synthetase reaction. Then glutamine is transferred to nerve terminals by various glutamine 
transporters. In the terminals glutamine could act as a precursor of glutamate, aspartate and GABA 
through phosphate activated glutaminase, which are active in both glutamatergic and GABAergic 
terminals (7) (Paper III).
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